Remove 2023 Remove Complication Remove Electronics Remove Provider
article thumbnail

Transition Plans for Covid-19 Products are Amongst CDRH FY2023 Priorities

FDA Law Blog

On October 17, 2022, FDA published the list of CDRH proposed guidances for FY 2023 (see here ). electronic thermometers, single lumen needles, piston syringes). As we emphasized in our previous blog post , the termination of COVID-19 PHE could complicate the business plan for some medical product companies.

Medical 52
article thumbnail

The Good, Bad, and Ugly side of 510(k)s—HP&M’s Early Experience with the eSTAR Template for 510(k)s

FDA Law Blog

FDA announced on October 3, 2022 that the voluntary electronic Submission Template And Resource (eSTAR) templates would be required beginning October 1, 2023, as we blogged about here. There are additionally places to provide attachments for test reports and other supporting documents. New Labeling Requirements.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Future Directions in Opioid Prescribing Patterns for Patients with Chronic Pain [Prescribing and pharmacotherapeutics]

Annals of Family Medicine

Objective: 1) Demonstrate the feasibility of collecting data from prescription drug monitoring programs (PDMPs) for population health reporting, 2) analyze trends in PDMP and electronic health record patient data relative to CDC guidelines and 3) identify use of patient-centered measures for pain management in primary care.

Patients 130
article thumbnail

Rewiring the body clock: Deep brain imaging reveals unexpected complexity in jet lag adjustment

Medical Xpress

But what we observed was much more complicated." The content is provided for information purposes only. The traditional model is simple: SCN neurons were believed to act like runners in a relay race, passing the light signal along in a linear chain. Some SCN neurons were activated by light, while others were inhibited.

Provider 109
article thumbnail

Texas invests $50M in psychedelic drug research to treat addiction

Medical Xpress

The content is provided for information purposes only. Citation : Texas invests $50M in psychedelic drug research to treat addiction (2025, June 16) retrieved 16 June 2025 from [link] This document is subject to copyright. Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.

article thumbnail

Allowing Patients to Die: Louise Aronson and Bill Andereck

GeriPal

Louise 05:02 Yes, well, I don’t know about 2024, but in 2023, yes, it could happen. Alex 15:13 This is really complicated. And it’s not the same, but it does provide information. And in fact, after a complicated ethics issue, we will oftentimes go in and try and debrief them. It happened to my mother.

article thumbnail

Buckle Up: DOJ Initiates Rulemaking to Reschedule Marijuana

FDA Law Blog

The Attorney General also released DOJ’s Office of Legal Counsel (“OLC”) opinions providing the rationale and support for the NPRM. Public comments must be submitted electronically or postmarked on or before July 22, 2024, 60 days after publication in the Federal Register. 29, 2023) (“Basis”); NPRM at 44,603. 21 U.S.C. §